Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Patient Reported Symptoms and Tryptase Levels in WHO-Defined Systemic Mastocytosis (SM) Versus Mast Cell Activation Syndrome (MCAS) Versus Neither

Darci Zblewski, CNP, Ramy A. Abdelrahman, MBBCh, Dong Chen, MD PhD, Joseph H. Butterfield, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 3204.

https://doi.org/10.1182/blood.V124.21.3204.3204

Published: 2014

Journal Articles

Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients

Animesh Pardanani, MBBS, PhD, Ramy A. Abdelrahman, MBBCh, Christy Finke, BS, Terra L Lasho, PhD, Kebede Begna, MD, Aref Al-Kali, MD, William J. Hogan, MBChB, Mark R. Litzow, MD, Curtis A. Hanson, MD, Rhett Ketterling, MD, Ayalew Tefferi, MD

Blood (2014) 124 (21): 3162.

https://doi.org/10.1182/blood.V124.21.3162.3162

Published: 2014

Journal Articles

Momelotinib Treatment-Associated Neuropathy: Prevalence, Risk Factors and Outcome in 100 Patients with Myelofibrosis

Ramy A. Abdelrahman, MBBCh, Kebede Begna, MD, Aref Al-Kali, MD, William J. Hogan, MBChB, Mark Litzow, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2014) 124 (21): 1837.

https://doi.org/10.1182/blood.V124.21.1837.1837

Published: 2014

Journal Articles

Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients

Animesh Pardanani, MBBS, PhD, Ramy A Abdelrahman, MBBCh, Kebede Begna, MD, Darci Zblewski, RN, CNP, Aref Al-Kali, MD, Mrinal M. Patnaik, MBBS, William Hogan, MD, Terra L Lasho, MT, (ASCP), Christy Finke, BS, Curtis A. Hanson, MD, Mark R. Litzow, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 4048.

https://doi.org/10.1182/blood.V122.21.4048.4048

Published: 2013

Journal Articles

Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide

Animesh Pardanani, MBBS, PhD, Ramy A. Abdelrahman, MBBCh, Kebede Begna, MD, Darci Zblewski, RN, CNP, Aref Al-Kali, MD, Mrinal M. Patnaik, MBBS, William Hogan, MD, Curtis A. Hanson, MD, Mark R. Litzow, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 4049.

https://doi.org/10.1182/blood.V122.21.4049.4049

Published: 2013

Journal Articles

Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival

Ramy A. Abdelrahman, MBBCh, Kebede Begna, MD, Darci Zblewski, RN, CNP, Aref Al-Kali, MD, Mrinal M. Patnaik, MBBS, William Hogan, MD, Ryan A Knudson, Rhett P Ketterling, Curtis A. Hanson, MD, Mark R. Litzow, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2013) 122 (21): 2821.

https://doi.org/10.1182/blood.V122.21.2821.2821

Published: 2013

Journal Articles

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

Animesh D. Pardanani, MBBS, PhD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Ramy A. Abdelrahman, MBBCh, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 2824.

https://doi.org/10.1182/blood.V122.21.2824.2824

Published: 2013

NARROW

Patient Reported Symptoms and Tryptase Levels in WHO-Defined Systemic Mastocytosis (SM) Versus Mast Cell Activation Syndrome (MCAS) Versus Neither

Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients

Momelotinib Treatment-Associated Neuropathy: Prevalence, Risk Factors and Outcome in 100 Patients with Myelofibrosis

Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients

Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide

Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Patient Reported Symptoms and Tryptase Levels in WHO-Defined Systemic Mastocytosis (SM) Versus Mast Cell Activation Syndrome (MCAS) Versus Neither

Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients

Momelotinib Treatment-Associated Neuropathy: Prevalence, Risk Factors and Outcome in 100 Patients with Myelofibrosis

Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients

Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide

Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival

Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only